BLA 761164 · Recordati Rare Diseases, Inc.
Enjaymo
Sutimlimab-Jome · Injection · Classical Complement Pathway Inhibitor
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Feb 4, 2022: To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease
Last checked: Nov 20, 2026Latest source record: Feb 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Feb 4, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
3
3 Phase 3, 0 recruiting
FAERS reports
321
180 serious, 54 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 2, 2026.
ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). ( 1 ) Cold Agglutinin Disease ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).
Mechanism: Sutimlimab-jome is an immunoglobulin G (IgG), subclass 4 (IgG4) monoclonal antibody (mAb) that inhibits the classical complement pathway (CP) and specifically binds to complement protein component 1, s subcomponent (C1s), a serine protease which cleaves C4. Sutimlimab-jome does not inhibit the lectin and alternative pathways. Inhibition of the classical complement pathway at the level of C1s prevents deposition of complement opsonins on the surface of RBCs, resulting in inhibition of hemolysis in patients with CAD.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 25, 2023 Supplement 3 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
- Feb 4, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- ENJAYMO · SUTIMLIMAB-JOME 1,100MG/22ML(50MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sutimlimab" as an intervention, any sponsor and status, largest first.
- A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood TransfusionPivotal-lookingCompleted
Bioverativ, a Sanofi companySanofi (SNY)
NCT03347422 · 42 participants · Start Mar 17, 2018 · Primary completion Dec 3, 2021
Drug: sutimlimab (BIVV009); placebo · For: Cold Agglutinin Disease
Sites: Tucson, Arizona; Los Angeles, California; Georgetown, District of Columbia · 53 sites in all
- A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)Pivotal-lookingCompleted
Bioverativ, a Sanofi companySanofi (SNY)
NCT03347396 · 24 participants · Start Mar 5, 2018 · Primary completion Oct 5, 2021
Drug: BIVV009 · For: Agglutinin Disease, Cold
Sites: Tucson, Arizona; Los Angeles, California; Whittier, California · 49 sites in all
- Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in JapanPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT05132127 · 7 participants · Start Nov 11, 2021 · Primary completion Nov 15, 2022
Drug: sutimlimab · For: Cold Agglutinin Disease
Sites: Ishikawa, Japan; Kanagawa, Japan; Osaka, Japan · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use39
- haemoglobin decreased23
- arthralgia20
- fatigue18
- death16
- haemolysis16
- condition aggravated15
- drug ineffective13
- headache13
- covid-1912
- cyanosis11
- nausea11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 34 |
| 2023 | 59 |
| 2024 | 73 |
| 2025 | 72 |
| 2026 | 83 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Enjaymo (Sutimlimab-Jome)
2024 spending
$1.7M
Beneficiaries
12
75 claims
Per beneficiary
$142,475
$84.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $336,833 |
| 2023 | $1,291,730 |
| 2024 | $1,709,695 |
Part B: Enjaymo (Sutimlimab-Jome) · HCPCS J1302
2024 spending
$33.9M
Beneficiaries
180
2,560 claims
Per beneficiary
$188,146
2024 ASP limit $17.94 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $3,199,085 |
| 2023 | $23,534,880 |
| 2024 | $33,866,257 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sutimlimab in Cold Agglutinin Disease.
Röth A, Barcellini W, D'Sa S, et al. · N Engl J Med 2021 · Clinical Trial, Multicenter Study
- Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, et al. · Blood 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease.
Miyakawa Y, Sato E, Ogawa Y, et al. · Int J Hematol 2024 · Clinical Trial, Phase III, Multicenter Study
- Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease.
Frank T, Kovar A, Strougo A, et al. · J Pharmacol Exp Ther 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
- A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.
Bartko J, Schoergenhofer C, Schwameis M, et al. · Clin Pharmacol Ther 2018 · Clinical Trial, Phase I, Randomized Controlled Trial
- Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.
Gelbenegger G, Schoergenhofer C, Derhaschnig U, et al. · Blood Adv 2020 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Recordati Rare Diseases, Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.